- DehydraTECH™
is patent protected for multiple Active Pharmaceutical Ingredients (APIs)
including hemp oil CBD and cannabis, nicotine, non-steroidal
anti-inflammatory drugs, and fat-soluble vitamins
- Lexaria
has 16 patents granted and over 60 patent applications pending worldwide
- DehydraTECH™
shown to facilitate rapid uptake and highly targeted delivery of
pharmaceuticals to the brain
Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug
delivery platforms, is accelerating its patented DehydraTECH based drug
delivery technology and formulation development. Funding received from the
first tranche of Lexaria’s previously announced private placement of units,
issued at a price of $0.45 per unit, realized gross proceeds of $699,410, which
will be used to advance several company-wide goals (http://ibn.fm/hGP3x).
Earlier this year, Lexaria moved into its new head office
that includes a Health Canada licensed research and development laboratory that
is being used to conduct world-leading research into drug delivery methods and
improvements. In addition to accelerating research in the company’s DehydraTECH
drug delivery platform, Lexaria is also considering issuing a limited
commercial release of DehydraTECH version 2.0, which has been shown to deliver
811% more CBD into animal blood than generic industry control formulations, the
company stated in an update to shareholders (http://ibn.fm/cWL3T).
Lexaria’s focus on pioneering new technologies that can more
efficiently deliver APIs into the bloodstream, where they can have their
desired effect, includes developing an effective way to cross the
blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in
this arena as testing indicated 1,937% more CBD reached animal brain tissue
compared to generic industry control formulations.
Cannabidiol is emerging as a promising compound to treat or
prevent movement disorders, such as those seen in Parkinson’s disease patients,
according to an article published by the National Institutes of Health (http://ibn.fm/BTruO). Extending
the range of drugs available for therapeutic use to treat neurological conditions
such as Alzheimer’s and Parkinson’s disease is a critical area of study since
there currently is no effective treatment for these diseases, according to an
article in Physics World (http://ibn.fm/C3TcM).
Lexaria’s dedication to research and development can be seen
in its strong and growing intellectual property portfolio. As of August 2019,
the company’s patent portfolio includes approximately 60 patent applications
filed and pending in more than 40 countries around the world, with 16 patents
granted to date. Lexaria is expecting additional new patent awards both in the
U.S. and internationally.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
